Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nesiritide in Reversing Pulmonary Hypertension in Patients Undergoing CardioThoracic Surgery
NCT00075179Phase 4Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2003
- Primary completion
- Mar 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nesiritide in pulmonary hypertension (PH), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Patients with 20% reduction in mean pulmonary arterial (PA) pressure at 30 minutes. Started Dec 2003; status: terminated.
02
Drugs
nesiritide
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT00075179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00075179.